Login / Signup

Monkeypox Outbreak 2022: What We Know So Far and Its Potential Drug Targets and Management Strategies.

Ali A RabaanAbdul Hawil AbasTrina Ekawati TalleiMona A Al-ZaherNoor M Al-Sheefnull FatimawaliEsraa Z Al-NassEba A Al-EbrahimYunus EffendiRinaldi IdroesMather F AlhabibHussain A Al-FheidAhmad Akroman AdamTalhah Bin Emran
Published in: Journal of medical virology (2022)
Monkeypox is a rare zoonotic disease caused by infection with the monkeypox virus. The disease can result in flu-like symptoms, fever, and a persistent rash. The disease is currently spreading throughout the world and prevention and treatment efforts are being intensified. Although there is no treatment that has been specifically approved for monkeypox virus infection, infected patients may benefit from using certain antiviral medications that are typically prescribed for the treatment of smallpox. The drugs are tecovirimat, brincidofovir, and cidofovir, all of which are currently in short supply due to the spread of the monkeypox virus. Resistance is also a concern, as widespread replication of the monkeypox virus can lead to mutations that produce monkeypox viruses that are resistant to the currently available treatments. This article discusses monkeypox disease, potential drug targets, and management strategies to overcome monkeypox disease. With the discovery of new drugs, it is hoped that the problem of insufficient drugs will be resolved, and it is not anticipated that drug resistance will become a major issue in the near future. This article is protected by copyright. All rights reserved.
Keyphrases
  • small molecule
  • emergency department
  • drug induced
  • depressive symptoms
  • high throughput
  • single cell
  • electronic health record